Neurocrine Biosciences (NBIX) Tops Q1 EPS by 77c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/4/2026
- Dow claims record closing high, S&P 500 advances; chip selloff weighs on Nasdaq
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- HSBC stays aggressive on stocks, asks what could turn it bearish
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Crypto stocks sink as Bitcoin hits a 4-month low
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
- Navitas showcases 800V power delivery board at NVIDIA MGX ecosystem event
- Inotiv files for bankruptcy with $65 million financing commitment
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Wells Fargo Upgrades Oscar Health Inc (OSCR) to Equal Weight 'on Greater Confidence in Exchange Market Trajectory in 2026'
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
May 5, 2026 4:01 PM EDTTotal First-Quarter 2026 Net Product Sales of $811.0 Million,
An Increase of 44% Year-Over-Year
Announced Definitive Agreement to Acquire Soleno Therapeutics, Including VYKATTM XR (diazoxide
choline) for the Treatment of Hyperphagia in Prader-Willi Syndrome Expected to Close in Q2 2026
Initiated Phase 2 Clinical Study of NBI-1117570, a Dual M1 / M4 Selective Agonist, in Adults with
Schizophrenia
Reaffirmed 2026 Full-Year INGREZZA® (valbenazine) Net Sales Guidance of $2.7 - $2.8 Billion
SAN DIEGO, May 5,... More
